Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4321919 A
Publication typeGrant
Application numberUS 06/102,553
Publication date30 Mar 1982
Filing date11 Dec 1979
Priority date11 Dec 1979
Also published asCA1153334A1, DE3070398D1, EP0030358A2, EP0030358A3, EP0030358B1
Publication number06102553, 102553, US 4321919 A, US 4321919A, US-A-4321919, US4321919 A, US4321919A
InventorsRichard L. Edelson
Original AssigneeLeukocyte Research, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method and system for externally treating human blood
US 4321919 A
Abstract
A method and system are disclosed for externally treating human blood, with the objective of reducing the functioning lymphocyte population in the blood system of a human subject. According to the method, blood is withdrawn from the subject and passed through an ultraviolet radiation field in the presence of from about 1 nanogram to 100 micrograms per ml of blood, of a dissolved psoralen capable of forming photoadducts with DNA, to thereby effect covalent bonding between the psoralen and the nucleic acid of the lymphocytes, thereby altering the said nucleic acid and inhibiting the metabolic processes of the lymphocytes; and thereupon returning the irradiated blood to the subject. The withdrawn blood may be formed into an extracorporeal stream and flowed through a treatment station whereat the irradiation is effected, as for example by exposure to UV energy in the wave length range of from about 3200 to 4000 Angstroms; and such flow process may be conducted on a continuous basis. If desired, at least portions of the treated blood may then be separated, as for example by a continuous centrifuge, before returning the remaining diverted blood to the subject.
Images(1)
Previous page
Next page
Claims(16)
I claim:
1. A method for reducing the population of lymphocytes with intense metabolic activity in the blood supply of a human subject, comprising the steps of:
withdrawing whole blood from said subject, forming said whole blood into an extracorporeal stream, flowing said stream through a treatment station which comprises a thin chamber substantially transparent to UV radiation, irradiating said withdrawn whole blood in said treatment station with UV radiation in the presence of about 1 nanogram to 100 micrograms of a dissolved psoralen capable when activated by said UV radiation to effect chemical bonding between said psoralen and said lymphocytes, thereby selectively inhibiting the metabolic processes of said lymphocytes; and returning the irradiated whole blood to said subject.
2. A method in accordance with claim 1, wherein said psoralen comprises 8-MOP.
3. A method in accordance with claim 1, wherein said withdrawing of said whole blood, passage to such treatment station, and return of said whole blood to said subject, is carried out as a continuous operation.
4. A method in accordance with claim 3, wherein the flow rate of said extracorporeal bloodstream is in the range of from about 10 to 75 ml/min.
5. A method in accordance with claim 3, including the further step of separating at least portions of said lymphocyte population before returning said whole blood to said subject, by passing said bloodstream through a continuous flow centrifuge.
6. A method in accordance with claim 5, wherein excess quantities of said psoralen are removed from the extracorporeal stream by withdrawing blood plasma at said centrifuge and replacing same with fresh psoralen-free plasma.
7. A method in accordance with claim 1, including the further step of separating at least portions of said lymphocyte population before returning said whole blood to said subject.
8. A method in accordance with claim 1, wherein said whole blood is irradiated with photoenergy in the UVA wavelength range, and at a radiation dose level of from about 0.1 to 100 joules/cm2.
9. A method in accordance with claim 1, wherein said psoralen is dissolved in said whole blood by mixing same with said whole blood subsequent to withdrawing the whole blood from said subject.
10. A method in accordance with claim 1, wherein said psoralen is dissolved in said whole blood by administering said psoralen orally to said subject.
11. A method in accordance with claim 1, wherein said psoralen is methyl or methoxy substituted.
12. A method in accordance with claim 11, wherein said psoralen is methyl-substituted at one or more of the 4, 4', 5' and 8 positions.
13. A method in accordance with claim 12, wherein said psoralen comprises 4, 5',8-trimethylpsoralen.
14. A method for reducing the population of lymphocytes with intense metabolic activity in the blood supply of a human subject, comprising the steps of:
withdrawing whole blood from said subject, forming said whole blood into an extracorporeal stream, flowing said stream through a treatment station which comprises a thin chamber substantially transparent to UV radiation, irradiating said withdrawn whole blood in said treatment station with UV radiation in the presence of an effective amount of 8-methoxypsoralen within the range of from about 1 nanogram to 100 micrograms per ml of blood capable when activated by said UV radiation to effect chemical bonding between said 8-methoxypsoralen and said lymphocytes, thereby selectively inhibiting the metabolic processes of said lymphocytes; and returning the irradiated whole blood to said subject, wherein said process is carried out continuously.
15. The process of claim 14 wherein said chamber is a UV-transparent plastic.
16. The process of claim 14 wherein the psoralen, is an isotonic solution, is introduced into the extracorporeal stream.
Description
BACKGROUND OF INVENTION

This invention relates generally to methods and systems for medical treatment of the human body, and more specifically relates to a method and system usable in treating the blood supply of a human subject for the purpose of reducing the functioning lymphocyte population in the blood supply of such subject.

In a number of highly significant human diseases, including certain forms of leukemia, the population of certain types of leucocytes, including especially lymphocytes, increases inordinately in comparison to the other populations of nucleated cells in normal blood. While the excessive population of such lymphocytes represents a result of, rather than the underlying cause of the disease, the excessive lymphocyte population brings direct adverse effects to the patient if steps are not taken to reduce same. Complications thus rapidly develop which impair function of bodily organs, and eventually a life-threatening situation is presented.

It should also be appreciated that excessive increase in the lymphocyte population of the blood supply can occur in other human maladies, in addition to lymphocytic leukemias. Thus, for example, such results can obtain in consequence of severe allergic reactions to administered agents, including drugs or the like, or in many other lymphocyte-mediated diseases.

In addition to the development over the years of pharmaceutical agents and the like, which may nonspecifically reduce the lymphocyte population, e.g. by altering the underlying production rate of same, various techniques have from time to time been used in an effort to directly attack the problem, as for example by mechanically removing such lymphocytes from the blood supply. It is thus known, for example, to pass the blood supply through a continuous centrifuge, whereat one seeks to selectively remove lymphocytes to reduce the population of the latter in the thereby processed blood supply. In general, however, this method tends to be very inefficient, in part because the density differences between the blood fractions including the undesired lymphocytes and fractions which include desired blood components, is insufficient to assure that high percentages of the former are removed while retaining high proportions of the latter.

It is also well-known to treat diseases such as leukemia with high energy electromagnetic radiation, including in the X-ray region. While such treatment is often directed at internal bodily organs whereat the blood cells are being generated, it has also been known to irradiate the blood supply with x-radiation at a point external to the body (the blood having first been withdrawn), whereby the radiation is not rendered directly incident on the body or internal organs of same. This method, while powerful, is indiscriminate, in that the intensely disruptive energy, in addition to destroying undesirable cells, disables or destroys components of the blood which are desired to be retained in vital status.

For many years, it has been known that certain heterocyclic furocoumarins possess photoactive properties that render same useful in the treatment of certain human diseases. A noteworthy example of this occurs in certain recently reported methods for treatment of psoriasis.

The photoactive compounds referred to are all members of a group of coumarin derivatives which are commonly referred to as "psoralens", the basic member of which is the (photoactive) compound psoralen, having the structure: ##STR1##

The remaining compounds of interest for this invention (as will be discussed in greater detail hereinbelow) are all derivatives of psoralen, i.e. of structure (1). In accordance, however, with accepted terminology in the nomenclature of the pertinent chemical art, the phrase "psoralen" or "a psoralen" will be used at places in this specification to refer to certain derivatives of structure (1) which include "psoralen" in their accepted name, such as 8-methoxypsoralen, 5-methoxypsoralen, etc.

In an article appearing in the New England Journal of Medicine, Volume 291, No. 23 for Dec. 5, 1974, John A. Parrish, M.D. et al, thus report a method involving oral administration of 8-methoxypsoralen (8-MOP) to a patient who is thereafter treated by exposure to a high intensity longwavelength ultraviolet light source, i.e. to a source of ultraviolet radiation in the UVA wavelength region, and preferably in the wavelength range between about 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The highly successful treatment is deemed to be effective by interrupting the disease process in psoriasis, a disorder characterized by an accelerated cell cycle and rate of DNA synthesis. The treatment acts to inhibit DNA synthesis by formation of C-4 cyclo-addition products between the pyrimidine bases of the nucleic acids and psoralen molecule. Since the 5,6 double bond of the pyrimidine can photoreact with the psoralen molecule at either the 3,4 double bond of the pyrone ring or at the 4',5' double bond of the furan ring, two types of photoadducts are possible. In consequence formation of photo-induced DNA cross-links is enabled.

In this sequence of treatment thus employed in the treatment of psoriasis, it has been common to place the patient following administration of the psoralen, in a light box or other environment whereat the high intensity illumination is effected. It has come to the attention of investigators that a side effect resulting from the cited treatment, can occasionally be the destruction of certain nucleated blood cells. Investigation appears to establish that such result obtains because the incident UV radiation has sufficient penetrating power, to induce some bonding between the psoralen introduced into the bloodstream and the nucleic acid of the nucleated blood cells such as the lymphocytes. In consequence the metabolic processes of such modified lymphocytes are detrimentally affected, eventually leading to the inactivation and ultimate destruction of same. This type of phenomenon has been studied in vitro, and among other places, is reported in an article by G. Lischka et al appearing in Archives for Dermatological Research, 259, 293-298 (1977). Of interest for present purposes is that the reported phenomenon is regarded as an undesirable side effect, which is incident to the beneficial results otherwise achieved during treatment of psoriasis.

SUMMARY OF INVENTION

Now, in accordance with the present invention, a method and system has been found which enables safe and effective reduction of the functioning lymphocyte population in the blood supply of a human subject. According to the method of invention, blood requiring such treatment, is withdrawn from the subject and irradiated with UVA radiation in a preferred wavelength range of from about 3200 to 4000 Angstroms, in the presence of from about 1 nanogram to 100 microgram per ml of blood of a dissolved psoralen of the type capable of forming photoadducts with DNA, to thereby effect covalent bonding between the psoralen and the nucleic acid of the lymphocytes present in the blood. The said nucleic acid is thereby altered to inhibit the metabolic processes of the said lymphocytes, after which the irradiated blood is returned to the human subject.

The withdrawn blood can be treated in batch, but preferably is formed into an extracorporeal stream and passed through a treatment station whereat the irradiation is effected. Such treatment station may take the form of an extended flattened tubular passageway, the walls of which are substantially transparent to the incident long-wave UV energy (UVA) used to activate the psoralen. Typical radiation doses range from about 0.1 to 100 joules per cm2 of blood surface where the process is carried out on a continuous or discontinuous basis, and typical flow rates through the irradiation station can be in the range of from about 10 to 75 ml/min.

Following treatment, the entire batch, or irradiated flow of diverted blood, can be returned to the patient with all blood components intact. The lymphocytes, however, by virtue of the treatment, have been so altered that their metabolic functioning is rapidly impaired, and especially the ability of same to divide, in consequence of which destruction of the impaired lymphocytes rapidly occurs. Moreover, the impairment and destruction tends to be selective in certain diseases such as leukemia, to the cells most sought to be reduced, by virtue of the fact that it is such cells which are undergoing the most intense metabolic activities to begin with, whereby they are the cells most subject to disablement by the present process.

A preferred psoralen for use in the process of the present invention is 8-methyoxypsoralen (8-MOP, also known as methoxsalen). Other photoactive psoralens useful in practice of the present invention include psoralen itself, i.e. structure (1), and 4,5',8-trimethylpsoralen. Less preferred, but still useful photoactive psoralens for use in the invention include 5-methoxypsoralen, 4-methylpsoralen, 4,4-dimethylpsoralen, 4,5'-dimethylpsoralen, and 4',8-dimethylpsoralen.

Further discussion of these photoactive psoralens may be found in the tutorial article entitled Photobiology and Photochemistry of Furocoumarins (Psoralens) by M. A. Pathak et al, which article appears as Chapter 22 of the work Sunlight and Man, edited by Thomas B. Fitzpatrick et al, University of Tokyo Press (1974). This article observes (which is appropriate for present purposes) that the most effective photoactive psoralens include the compound psoralen proper, i.e. structure (1), and derivatives of structure (1) wherein methyl or methoxy groups are substituted at one or more of the 4,4',5' and 8 positions, as for example in the aforementioned 8-MOP, which has the structure: ##STR2## and 4,5',8-trimethylpsoralen, which has the structure: ##STR3##

As aforementioned, the reactive sites of the nucleic acids are considered to be the pyrimidine bases, and it is believed that the photoinduced reaction of the present invention involves the activated psoralen and one or more of the pyrimidine bases normally present in nucleic acids, such as thymine, cytosine, uracil or so forth. A C4 cyclo-addition takes place; the pyrimidine bases always react with their 5,6 double bond, while the psoralens can react with either their 3,4 double bond or with their 4',5' double bond. In consequence two types of photo-adducts can be obtained. This ability to bond at two regions of the linear psoralen structure enables the said structure upon photo-activation to link to one pyrimidine base, or to two pyrimidine bases which engage both of the reactive double bonds of the psoralen structure. Where this double linking occurs, cross-linking can be effected between the two strands of DNA, which is particularly effective in inhibiting the metabolic functions of the associated nucleated cells, such as the lymphocytes.

BRIEF DESCRIPTION OF DRAWINGS

The invention is diagrammatically illustrated, by way of example, in the drawings appended hereto, in which:

FIG. 1 is a schematic flow diagram illustrating a preferred embodiment of a system operating in accordance with the present invention;

FIG. 2 is a schematic elevational view of the irradiation station portion of the FIG. 1 system;

FIG. 3 is a plan view, schematic in nature, of one embodiment of the irradiation station of FIG. 2; and

FIGS. 4 and 5 are cross-sectional views, taken along the lines 4--4 and 5--5 of FIG. 3, and illustrate the configurations of the flow passageway and the output passage for the FIG. 3 device.

DESCRIPTION OF PREFERRED EMBODIMENT

In FIG. 1 herein a schematic diagram appears of a system 10 in accordance with the present invention. Except for the irradiation station, the bulk of the components of system 10 are per se conventional and known in the art; and hence it is not deemed appropriate or necessary to vastly detail same.

As indicated in the Figure, blood may initially be withdrawn from the human subject, as at 12. Typically the blood is withdrawn via a donor needle, which may e.g. be emplaced at the right antecubital vein. In the showing of FIG. 1, it is assumed that the processing of blood pursuant to the invention is conducted on a continuous basis, i,e. for purposes of the present discussion the flow may be regarded as continuous from withdrawal at 12, to final return of the blood to the subject at 14. Such return 14 is typically effected via a recipient needle positioned in the left antecubital vein. Where the flow is indeed continuous in this manner, a typical blood flow utilizable in practice of the invention is in range of from about 10 to 75 ml/min, with a more preferred range being from about 40 to 50 ml/min. The indicated flow rates are effected by means of a pump 16, which is positioned in the extracorporeal blood flow stream generally indicated at 18, and may comprise one of numerous types of pumps used for blood flow treatment purposes, including such pumps as those available from Haemonetics Corp. under Model Designation 30.

As is known in the pertinent medical art, anti-coagulants are preferably injected into the extracorporeal blood flow stream at 20, i.e. close to the point of blood withdrawal. Such anti-coagulants can comprise solutions of acid citrate dextrose and/or of heparin, or of other known compositions useful for this purpose.

An occluded vein sensor 22 is preferably provided in stream 18 for purposes, as known in the art. Such sensor basically comprises a reservoir or buffer volume, the object of which is to prevent or inhibit generation or continued existence of bubbles in the blood flow stream.

Pursuant to a preferred mode of practicing the present invention, the photoactive psoralen is preferably added to the blood of the human subject external to such subject; and thus as shown in the system 10 of FIG. 1, may be provided to the flowing blood downstream of pump 16, and just upstream of where the blood enters the irradiation station 24.

As has been discussed under the "Summary of Invention" the preferred psoralen for use in the process of the invention is 8-methoxypsoralen (8-MOP). As also discussed, other photoactive psoralens as previously described, are also utilizable in the method of the invention. The basic technique used in introducing the psoralen, is to disolve same in an isotonic solution, which thereafter is directly injected into the flowing blood stream, as at 26. The psoralen is injected at a rate in comparison to the blood flow rate, as to achieve a concentration in the blood thereafter passed to irradiation station 24, of from about 1 nanogram to 100 micrograms of dissolved psoralen per ml of blood.

In the foregoing connection it should be appreciated that the primary objective of the operations thus far described is one of achieving the desired dissolved concentration of the photoactive psoralen prior to introduction of the blood to the irradiation station. In accordance with a further aspect of the invention, it will therefore be appreciated that the said photoactive compound need not necessarily be directly introduced by injection into the extracorporeal blood stream 18 flowing in FIG. 1. Rather, it is also acceptable to achieve the desired psoralen concentration levels by orally or otherwise administering the compound directly to the patient.

Indeed, in those instances of the prior art which have been heretofore discussed, wherein 8-MOP has been utilized in treatment of psoriasis, it has been usual for the psoralen to be orally administered. Where, pursuant to the invention, the psoralen is thus orally administered, it can be provided in oral dosages of from about 0.6 to 1.0 mg per kg of body weight. The desired concentration range in the blood used for practice of the invention, is then achieved in about two hours from oral administration.

However, it is preferred to introduce the psoralen to the extracorporeal stream (or to an extracorporeal batch volume) in order to achieve more exact concentration levels; and further, to avoid or minimize possible side effects and the like, which can occur from administration of any drug directly to the body system.

At irradiation station 24, consisting of an irradiation chamber 28 and radiation source 30, the blood now carrying in solution the desired psoralen concentration, is subjected to ultraviolet radiation in the UVA portion of the spectrum. Such UVA portion of the spectrum includes primarily wave lengths in the range from about 3200 to 4600 Angstroms. For present purposes it is preferred to use a radiation source having the bulk of its spectral components in the 3200 to 4000 Angstrom range, with peak intensities at about 3600 to 3700 Angstroms. Such radiation passes readily through conventional clear plastic tubing.

In FIG. 2, a schematic elevational view appears of an irradiation station 24 of a type suitable for use with the invention. Such station consists of a blood treatment or irradiation chamber 28, having an inlet 31 and an outlet 32, enabling blood flow through the chamber, and a spaced source 30 of UVA radiation. The chamber 28 can take various forms, with the principal requirement for same being that the wall 34 of same opposed to source 30, be substantially transparent to the incident UVA radiation. The said chamber (or at least wall 34) can therefore typically be comprised of various substantially UVA-transparent plastics, as are commonly used in tubing constructed for administration of standard intravenous solutions, such as polyvinyl chloride and the like.

In one embodiment of chamber 28, the said device can comprise a simple envelope, i.e., the central void 36 is substantially of thin rectangular cross-section. Where, however, the blood is to be treated as preferred, on a continuous basis, superior flow characteristics and better control of the exposure time can be achieved where blood treatment chamber 28 has a configuration as shown in FIGS. 3, 4 and 5. In this instance a tubular coil 38, which in cross-section (FIG. 5) is flattened to a very elongated elipse, is fixedly maintained in or upon a support plate 40. The blood flow inlet 30 to the coil is of circular cross section, and in terms of FIG. 1 is at a point downstream of pump 16. The feed-in for the psoralen compound is schematically depicted at 26. The highly flattened cross-section of the coil enables good flow for the blood passing through the coil, but, more importantly, enables good exposure of the flowing blood to the incident UVA radiation. The outlet 32 is again returned to a circular cross-section.

UVA source 30 may comprise one or a plurality of side-by-side or otherwise arranged UVA light sources 41, each of which may be backed by a reflector 42. The UVA sources can comprise commercially available lamps, numerous types of which are known in the art.

By way of example, source 30 can comprise a single 1000 watt Hg lamp of the type available from Oriel Corporation of Stamford, Conn., under Model designation 6287. When used with appropriate filters this source provides a good relatively continuous spectrum of high intensity radiation between 3200 and 4000 Angstroms, with a peak emission at about 3650 Angstroms. The said lamp with a suitable reflector can be positioned approximately 5 to 30 cm from chamber 28. With the flow rates utilized in accordance with one aspect of the invention, such a source will provide absorbed energy in the flowing blood within the range of interest for practicing the method of the invention.

The blood flow from irradiation station 24 proceeding as shown in FIG. 1 via outlet 32, can be directly returned to the subject at 14. Under these circumstances, the modified lymphocyes, i.e. wherein bonding of nucleic acid to the photo-activated psoralen compounds has been effected, are impaired in their metabolic processes, in consequence of which the said lymphocytes will be rapidly broken down and destroyed by normal processes occurring in the subject. Since further, and as already discussed, the metabolic processes in the abnormal lymphocytes associated with disease conditions are usually accelerated, the breakdown in functioning, and the destruction of such abnormal lymphocytes, is accelerated beyond the corresponding effects on rate of normal lymphocytes, thereby contributing to the destruction of the abnormal lymphocyte population in the blood supply of the subject.

The burden placed upon the body's organ system, however, can be further alleviated, by utilizing in conjunction with the present system, a continuous centrifuge 44, which device serves several functions.

It is to be noted that continuous centrifuges of the type here utilized, have been long employed in blood flow processing systems commercially available from several manufacturers, including Haemonetics Corporation of Braintree, Mass., and the IBM Corporation, Medicals Products Division, of Monsey, N.Y. In the prior art systems in which such devices have been utilized all elements of FIG. 1 have been present, with the singularly important exception of the irradiation station 24. The function of the continuous centrifuge in such prior art systems has been one of separating excess lymphocytes or other blood components of interest. Where so used, a detriment of such system was the inefficiency of same, i.e. the centrifuging process can at best remove about 40 to 50% of the lymphocytes, and unfortunately also removes numerous components which are in fact desired to be retained.

In the system 10 of the present invention, two functions can be performed by the continuous centrifuge 44. One of these, is removal of lymphocytes, as previously discussed. Because the present invention, however, relies primarily on impairment of function of the lymphocytes to ultimately reduce the functioning population of same, the centrifuge 44 need not be relied upon to the extent that same has been in the aforementioned prior art arrangements. From a mechanical viewpoint, this implies that one need not work as close to the specific gravity interface between the lymphocyte fraction of the blood and the desirable fractions of the blood which one seeks to retain. Thus one can avoid undue separation of those desired fractions of the whole blood.

The continuous centrifuge 44, may further be utilized for an additional important purpose. In particular, some or virtually all of the blood plasma may be removed at 46 and replaced with fresh plasma at 48. This washing technique enables one to effectively withdraw the excess psoralen compounds which may be present in the blood plasma, replacing the plasma at 46 with psoralen-free isotonic fluid. Thus, when the blood is returned to the subject at 14, it is substantially free of any excess psoralens, i.e. other that those which have combined with the nucleic acid components of the lymphocytes in the manner desired.

It should also be reemphasized that while the preferred mode of practicing the present invention, as illustrated in FIG. 1, contemplates a continuous operation, the blood treatment pursuant to the invention can be effected by batched techniques. Thus for example a distinct, fixed quantity of blood may initially be withdrawn from the subject. Such quantity or batch, may already have present therein the desired quantities of disolved psoralen, i.e. by prior adminstration to the patient; or the said psoralen may be admixed externally with the withdrawn blood. The said blood batch bearing the psoralen may then be provided to an irradiation station, where the desired quantity of UVA energy is rendered incident upon same. During this process the batch of blood can be flowed through the station as previously discussed, or if the quantity of blood is appropriate and the blood treatment chamber 28 of appropriate dimensions, the batch can simply be treated under static conditions until the desired energy has been dissipated. Thereafter, the treated blood is taken from the irradiation station, and either centrifuged as above discussed, or directly returned to the subject.

While the present invention has been particularly described in terms of specific embodiments thereof, it will be understood in view of the present disclosure, that numerous variations upon the invention are now enabled to those skilled in the art, which variations yet reside within the scope of the present invention. Accordingly, the invention is to be broadly construed, and limited only by the scope and spirit of the claims now appended hereto.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US1683877 *3 Mar 192711 Sep 1928Edblom Lester AMeans for treating blood-stream infections
US3788319 *30 Jul 197129 Jan 1974Univ Iowa Res FoundSystem for exchanging blood ultrafiltrate
Non-Patent Citations
Reference
1Bordin, Fand Baccichetti, Furocoumarin Photosensitive Effect on Virus-Producing Graffi Leukemia Cells, 1974.
2Psoralen Photosensitization of LI210 Leukemia Cells . . . Carlasse, F. et al, 2, Naturforsch, 33c, 92-95, 1978.
3Sunlight and Man, Chapt. 22, Fitzpatrick (ed), U. of Tokyo Press, 1974.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4568328 *29 Oct 19844 Feb 1986Extracorporeal Medical Specialties, Inc.Automated photophoresis blood portion control methods and apparatus
US4573960 *29 Oct 19844 Mar 1986Extracorporeal Medical Specialties, Inc.Three phase irradiation treatment process
US4612007 *8 Dec 198216 Sep 1986Edelson Richard LeslieMethod and system for externally treating the blood
US4613322 *29 Mar 198323 Sep 1986Edelson Richard LeslieMethod and system for externally treating the blood
US4683889 *21 Jun 19854 Aug 1987Frederic A. Bourke, Jr.Method and system for externally treating the blood
US4684521 *21 Jun 19854 Aug 1987Frederic A. Bourke, Jr.Method and system for externally treating the blood
US4708715 *27 Feb 198624 Nov 1987Mcneilab, Inc.Light array assembly for photoactivation patient treatment system
US4727027 *7 Oct 198523 Feb 1988Diamond Scientific Co.Furocoumarin derivative and ultraviolet irradiation
US4748120 *20 Oct 198631 May 1988Diamond Scientific Co.Photochemical decontamination treatment of whole blood or blood components
US4775625 *21 Nov 19864 Oct 1988The Medical College Of Wisconsin, Inc.Excitation with visible light
US4838852 *27 Mar 198713 Jun 1989Therakos, Inc.Contacting with antigen, withdrawal blood, irradiating, returning to patient
US4861704 *8 Oct 198629 Aug 1989The Trustees Of Columbia University In The City Of New YorkProcesses for development of acceptance of transplanted organs and tissues
US4915683 *10 Mar 198710 Apr 1990The Medical College Of Wisconsin, Inc.Antiviral method, agents and apparatus
US4921473 *2 Feb 19891 May 1990Therakos, Inc.Multicomponent fluid separation and irradiation system
US4946438 *12 Jun 19897 Aug 1990The Trustees Of Columbia University In The City Of New YorkProcess for development of acceptance of transplanted organs and tissues
US4960408 *10 Jan 19892 Oct 1990Klainer Albert STreatment methods and vaccines for stimulating an immunological response against retroviruses
US4998931 *21 Dec 198812 Mar 1991Puget Sound Blood CenterUltraviolet radiation treatment of tissues for transfusion or transplantation
US4999375 *11 Apr 198912 Mar 1991Hoffmann-La Roche Inc.Psoralen reagent compositions for extracorporeal treatment of blood
US5036102 *14 Sep 199030 Jul 1991Hoffmann-La Roche Inc.Extra-corporeal infusion into blood
US5039483 *8 Feb 199013 Aug 1991The Medical College Of Wisconsin, Inc.Antiprotozoan method
US5116864 *9 Apr 199126 May 1992Indiana University FoundationMethod for preventing restenosis following reconfiguration of body vessels
US5176921 *11 May 19895 Jan 1993Diamond Scientific Co.Addition of a psoralen and irradiation
US5263925 *22 Jul 199123 Nov 1993Gilmore Jr Thomas FPhotopheresis blood treatment
US5284869 *17 Dec 19918 Feb 1994Emil BisacciaPhotophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5288605 *2 Mar 199222 Feb 1994Steritech, Inc.Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen
US5290221 *17 Dec 19921 Mar 1994Baxter International Inc.Systems for eradicating contaminants using photoactive materials in fluids like blood
US5300019 *17 Dec 19925 Apr 1994Baxter International Inc.Systems and methods for eradicating contaminants using photoactive materials in fluids like blood
US5304113 *2 Nov 199019 Apr 1994The Mcw Research Foundation, Inc.Method of eradicating infectious biological contaminants
US5418130 *13 Jul 199323 May 1995Cryopharm CorporationPhosphonium or ammonium halo-psoralen
US5482828 *7 Mar 19949 Jan 1996Steritech, Inc.Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen
US5536238 *11 Aug 199416 Jul 1996Baxter International Inc.Systems and methods for simultaneously removing free and entrained contaminants in fluids like blood using photoactive therapy and cellular separation techniques
US5569304 *13 May 199429 Oct 1996Ulrich; Heinrich C.Apparatus for inducing bloodlessness at the extremities of a patient
US5669396 *16 Jan 199623 Sep 1997President And Fellows Of Harvard CollegeBlood test; using antibodies
US5868695 *28 Dec 19939 Feb 1999Baxter International Inc.System for treating a fluid carrying a contaminant
US5951509 *19 Nov 199714 Sep 1999Therakos, Inc.Blood product irradiation device incorporating agitation
US5984887 *26 Mar 199716 Nov 1999Therakos, Inc.Photopheresis treatment of leukocytes
US5985914 *8 Jul 199816 Nov 1999Therakos, Inc.Treatment of inflammatory disorders of the bowel and urinary bladder
US6113566 *15 Dec 19985 Sep 2000Foundation For Blood Irradiation Inc.Ultraviolet blood irradiation method and apparatus
US6133460 *20 Nov 199817 Oct 2000Cerus CorporationHave primary amino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen which permit binding to nucleic acid of pathogens; conditions that photoactivate these psoralens result in inactivation of pathogens which contain nucleic acid
US618757214 Apr 199313 Feb 2001Baxter International Inc.Decontaminating blood and cell cultures by mixing with a chemical radiation sensitizer which does not bind to the membrane, freezing or freeze-drying the mixture, then exposing to electromagnetic radiation
US619413928 Sep 199927 Feb 2001Cerus CorporationUsing a psoralen compound
US62195849 Jul 199917 Apr 2001Therakos, Inc.Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy
US62289958 Apr 19978 May 2001Therakos, Inc.Removing psorlen or degradation products by contacting blood or blood products with absorbent beads or fibers including ion exchange resins, polystyrene, or polystyrene copolymerized with divinylbenzene; then collecting blood
US62583194 Sep 199810 Jul 2001Cerus CorporationDevice and method for photoactivation
US625857721 Jul 199810 Jul 2001Gambro, Inc.Adding nontoxic amount of endogenous photosensitizer to fluid, exposing to photoradiation to activate sensitizer and allowing it to deactivate the microorganism; viral decontamination of blood and blood products
US626812019 Oct 199931 Jul 2001Gambro, Inc.Isoalloxazine derivatives to neutralize biological contaminants
US635523821 Mar 199712 Mar 2002Yale UniversitySpecific immune system modulation
US64333438 Jul 199913 Aug 2002Cerus CorporationDevice and method for photoactivation
US64552869 Feb 200024 Sep 2002Cerus CorporationPsoralens for pathogen inactivation
US646156711 Jun 20018 Oct 2002Cerus CorporationDevice and method for photoactivation
US646905222 Jan 200122 Oct 2002Cerus CorporationCompounds for the photodecontamination of pathogens in blood
US64953663 Sep 199917 Dec 2002Therakos, Inc.Method for pumping or delivering fluids utilizing a flexible vessel subject to controlled pressures within another pressure vessel. the pressure vessel can be sourced with positive and/or negative (e.g., vacuum) pressure.
US650369916 Aug 19997 Jan 2003Cerus CorporationMethod for photodecontamination of pathogens in blood using 5'-primary aminopsoralens
US652485513 Aug 200125 Feb 2003Richard Leslie EdelsonMethods for inducing the differentiation of monocytes into functional dendritic cells
US658674925 Jun 20021 Jul 2003Cerus CorporationDevice and method for photoactivation
US660772213 Aug 200119 Aug 2003Richard Leslie EdelsonMethods for inducing the differentiation of monocytes into functional dendritic cells
US66800256 Sep 200220 Jan 2004Cerus CorporationDevice and method for photoactivation
US66864803 Jun 20023 Feb 2004Cerus CorporationPsoralen compounds with aminoalkyl groups on the 5' position and optional alkyl groups on positions 4,4' and 8 that bind to nucleic acid of pathogens, and under photoactivation crosslink the nucleic acid, inactivating the pathogen
US6719715 *16 Mar 200113 Apr 2004Vasogen Ireland LimitedApparatus and process for conditioning organic fluid
US679364321 Apr 200021 Sep 2004Therakos, Inc.Low extracorporeal volume treatment system
US680043229 Sep 20005 Oct 2004Baxter International Inc.Comprises irradiating methylene blue in a sterile container with a suitable intensity and wavelength for activation; for use in transfusions and transplants
US68283235 Feb 20017 Dec 2004Gambro, Inc.Isoalloxazine derivatives to neutralize biological contaminants
US694975330 Jun 200327 Sep 2005Cerus CorporationDevice and method for photoactivation
US70491103 Feb 200323 May 2006Gambro, Inc.Inactivation of West Nile virus and malaria using photosensitizers
US708717716 Apr 20048 Aug 2006Baxter International Inc.method includes introducing a first fluid comprising first and second components having generally different densities into a centrifugal field and allowing interface to form between at least portions of first and second components at first location, moving interface, determining flow rates; efficiency
US709437815 Jun 200022 Aug 2006Gambro, Inc.Method and apparatus for inactivation of biological contaminants using photosensitizers
US710903113 Mar 200319 Sep 2006Yale UniversityMethods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
US718304524 Apr 200327 Feb 2007Gambro Inc.Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution
US718623027 Feb 20036 Mar 2007Therakos, IncMethod and apparatus for the continuous separation of biological fluids into components
US72110373 Sep 20031 May 2007Therakos, Inc.Multilayer housing; rotation
US72207476 May 200322 May 2007Gambro, Inc.Selected from the group consisting of alloxazines and photosensitizers
US739645229 Jun 20068 Jul 2008Fenwal, Inc.Apparatus for determining flow rates of biological fluids
US74791233 Sep 200320 Jan 2009Therakos, Inc.Blood component is subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component
US749815615 Jun 20053 Mar 2009Caridianbct Biotechnologies, LlcUse of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US750388919 Apr 200617 Mar 2009Dennis BriggsApparatus for the continuous separation of biological fluids into components and method of using same
US75346168 Nov 200219 May 2009Therakos, Inc.Uninterrupted flow pump apparatus and method
US764869931 Aug 200619 Jan 2010Caridianbct Biotechnologies, LlcPreventing transfusion related complications in a recipient of a blood transfusion
US7695675 *14 Mar 200513 Apr 2010Bayer Healthcare LlcMethod of inactivating microorganisms in a fluid using ultraviolet radiation
US785063419 Dec 200614 Dec 2010Therakos, Inc.Method for collecting a desired blood component and performing a photopheresis treatment
US78925353 Dec 200922 Feb 2011Caridianbct Biotechnologies, LlcPreventing transfusion related complications in a recipient of a blood transfusion
US790167325 Aug 20038 Mar 2011Caridianbct Biotechnologies, LlcBlood transfusion
US791447719 Apr 200629 Mar 2011Therakos, Inc.Apparatus for the continuous separation of biological fluids into components and method of using same
US798558831 Oct 200726 Jul 2011Caridianbct Biotechnologies, LlcInactivating leukocytes in whole blood via inoculation with riboflavin and exposure to ultraviolet radiation; blood transfusions
US805741829 Feb 200815 Nov 2011Nanospectra Biosciences, Inc.Devices and methods for extracorporeal ablation of circulating cells
US805778519 Dec 200515 Nov 2011Omj Ireland LimitedPhototherapy compositions and methods
US815308321 Apr 200910 Apr 2012Therakos, Inc.Uninterrupted flow pump apparatus and method
US848100823 Sep 20119 Jul 2013Therakos, Inc.Phototherapy compositions and methods
US867973617 Dec 200925 Mar 2014Terumo Bct Biotechnologies, LlcRemoval of adenine during a pathogen reduction process in whole blood or red blood cells by dilution
US87224228 Mar 201213 May 2014Therakos, Inc.Uninterrupted flow pump apparatus and method
US20130197419 *3 Jan 20131 Aug 2013Fenwal, Inc.Systems and methods for performing online extracorporeal photopheresis
EP0138489A1 *28 Sep 198424 Apr 1985McNeilab, Inc.Apparatus and methods for treating cells with radiation
EP0181732A2 *29 Oct 198521 May 1986McNeilab, Inc.Automated photophoresis blood portion control apparatus
EP0241123A126 Feb 198714 Oct 1987McNeilab, Inc.Improved valve apparatus for photoactivation patient treatment system
EP0392429A1 *9 Apr 199017 Oct 1990F. Hoffmann-La Roche AgPsoralen-reagens
EP1066842A27 Jul 200010 Jan 2001Therakos, Inc.Method and system for determining an effective amount of energy to deliver to fluids in phototherapy
EP1512421A22 Sep 20049 Mar 2005Therakos, Inc.Method for collecting a desired blood component and performing a photopheresis treatment
EP1550454A122 Dec 20046 Jul 2005Therakos, Inc.Extracorporeal photopheresis in combination with anti-TNF treatment
EP1990055A229 Nov 200212 Nov 2008Therakos, Inc.Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
EP2008676A22 Sep 200431 Dec 2008Therakos, Inc.Blood separation apparatus and method of using the same
EP2443922A12 Nov 200625 Apr 2012Therakos, Inc.The use of apoptotic cells ex vivo to generate regulatory T cells
EP2527458A22 May 200728 Nov 2012Therakos, Inc.Methods and reagents for detecting susceptilbility to graft versus host disease
EP2527838A22 May 200728 Nov 2012Therakos, Inc.Methods and reagents for detecting susceptibility to transplant related mortality (TRM)
EP2527839A22 May 200728 Nov 2012Therakos, Inc.Methods and reagents for detecting susceptilbility to transplant related mortality
EP2527840A22 May 200728 Nov 2012Therakos, Inc.Methods and reagents for detecting susceptilbility to graft versus host disease
WO1985000954A1 *22 Aug 198414 Mar 1985Univ ColumbiaProcesses for development of acceptance of transplanted organs and tissues
WO1990007952A1 *10 Jan 199026 Jul 1990Emil BisacciaTreatment methods and vaccines
WO1991012831A1 *22 Feb 19915 Sep 1991Inst Alternative HeilmethodenProcess and device for treating blood with oxygen and light
WO1992011059A1 *20 Dec 199121 Jun 1992Baxter IntSystems and methods for simultaneously removing free and entrained contaminants in fluids like blood using photoactive therapy and cellular separation techniques
WO1994013282A1 *17 Dec 199223 Jun 1994Emil BisacciaTreatment of lymes disease and associated debilitating conditions
WO1997036634A1 *26 Mar 19979 Oct 1997Therakos IncPhotopheresis treatment of chronic hcv infections
WO1998022164A119 Nov 199728 May 1998Therakos IncBlood product irradiation device incorporating agitation
WO1999002215A18 Jul 199821 Jan 1999Therakos IncTreatment of inflammatory disorders of the bowel and urinary bladder
WO2003075983A228 Feb 200318 Sep 2003Therakos IncMethod and apparatus for the continuous fractionation of biological fluids
Classifications
U.S. Classification604/6.08, 604/20, 604/28, 607/92, 422/44, 128/898, 128/DIG.3
International ClassificationA61N5/06, A61K35/14, A61M1/36
Cooperative ClassificationY10S128/03, A61M1/3681, A61M1/3686
European ClassificationA61M1/36R
Legal Events
DateCodeEventDescription
29 Oct 1982ASAssignment
Owner name: BOURKE, ELEANOR F.
Owner name: BOURKE, FREDERIC A., JR.,
Owner name: EDELSON, RICHARD L.
Owner name: EDELSON, RUTH C.
Free format text: CONDITIONAL ASSIGNMENT;ASSIGNOR:LEUKOCYTE RESEARCH, INC.;REEL/FRAME:004058/0043
Effective date: 19820729